Investors with the goal of beating the broader market often turn to stock selection. Strategic choices in individual stocks can have a profound impact on your wealth.
The closing price of Dexcom Inc (NASDAQ: DXCM) was $68.2 for the day, down -1.88% from the previous closing price of $69.51. In other words, the price has decreased by -$1.88 from its previous closing price. On the day, 6.15 million shares were traded. DXCM stock price reached its highest trading level at $69.98 during the session, while it also had its lowest trading level at $68.03.
Ratios:
Our analysis of DXCM’s different ratios will help us gain a deeper understanding of the company. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 9.13 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 46.86. For the most recent quarter (mrq), Quick Ratio is recorded 1.35 and its Current Ratio is at 1.52. In the meantime, Its Debt-to-Equity ratio is 1.00 whereas as Long-Term Debt/Eq ratio is at 0.52.
On August 21, 2025, Argus started tracking the stock assigning a Buy rating and target price of $100. On June 16, 2025, Truist started tracking the stock assigning a Buy rating and target price of $102.Truist initiated its Buy rating on June 16, 2025, with a $102 target price.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Sep 05 ’25 when Malady Kyle sold 667 shares for $80.86 per share. The transaction valued at 53,934 led to the insider holds 22,667 shares of the business.
Stern Sadie sold 1,466 shares of DXCM for $117,280 on Sep 04 ’25. The EVP, Chief HR Officer now owns 105,223 shares after completing the transaction at $80.00 per share. On Sep 05 ’25, another insider, Malady Kyle, who serves as the Director of the company, bought 667 shares for $80.86 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, DXCM now has a Market Capitalization of 26744987648 and an Enterprise Value of 26394988544. As of this moment, Dexcom’s Price-to-Earnings (P/E) ratio for their current fiscal year is 47.75, and their Forward P/E ratio for the next fiscal year is 26.34. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 1.94. For the stock, the TTM Price-to-Sale (P/S) ratio is 6.22 while its Price-to-Book (P/B) ratio in mrq is 10.40. Its current Enterprise Value per Revenue stands at 6.137 whereas that against EBITDA is 28.588.
Stock Price History:
The Beta on a monthly basis for DXCM is 1.48, which has changed by 0.022029042 over the last 52 weeks, in comparison to a change of 0.16333759 over the same period for the S&P500. Over the past 52 weeks, DXCM has reached a high of $93.25, while it has fallen to a 52-week low of $57.52. The 50-Day Moving Average of the stock is -14.15%, while the 200-Day Moving Average is calculated to be -14.63%.
Shares Statistics:
DXCM traded an average of 4.42M shares per day over the past three months and 7739970 shares per day over the past ten days. A total of 392.20M shares are outstanding, with a floating share count of 386.72M. Insiders hold about 1.39% of the company’s shares, while institutions hold 93.82% stake in the company. Shares short for DXCM as of 1756425600 were 11103110 with a Short Ratio of 2.51, compared to 1753920000 on 8486867. Therefore, it implies a Short% of Shares Outstanding of 11103110 and a Short% of Float of 3.63.
Earnings Estimates
The current market rating for Dexcom Inc (DXCM) reflects the collective analysis of 22.0 analysts closely monitoring its performance.The consensus estimate for the next quarter is $0.68, with high estimates of $0.74 and low estimates of $0.63.
Analysts are recommending an EPS of between $2.15 and $1.91 for the fiscal current year, implying an average EPS of $2.05. EPS for the following year is $2.56, with 24.0 analysts recommending between $2.91 and $2.3.
Revenue Estimates
It is expected that $90B in revenue will be generated in the current quarter, according to 22 analysts. It ranges from a high estimate of $1.21B to a low estimate of $1.15B. As of the current estimate, Dexcom Inc’s year-ago sales were $994.2MFor the next quarter, 22 analysts are estimating revenue of $1.25B. There is a high estimate of $1.31B for the next quarter, whereas the lowest estimate is $1.23B.
A total of 25 analysts have provided revenue estimates for DXCM’s current fiscal year. The highest revenue estimate was $4.68B, while the lowest revenue estimate was $4.61B, resulting in an average revenue estimate of $4.62B. In the same quarter a year ago, actual revenue was $4.03BBased on 25 analysts’ estimates, the company’s revenue will be $5.34B in the next fiscal year. The high estimate is $5.65B and the low estimate is $5.1B.
